Investing.com - Johnson & Johnson (NYSE:JNJ) posted fourth-quarter adjusted earnings and sales that topped analysts' estimates, as the pharmaceutical firm was boosted by demand for its cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback